Blood Cancer Journal

Article	Citations
Disparities in time to treatment with oral antimyeloma medications	353
BCR::ABL1-positive acute lymphoblastic leukemia as a high-risk feature of central nervous system relapse after allogeneic hematopoietic cell transplantation	160
Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report	146
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine	101
Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes	101
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib	93
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study	90
Correspondence on: Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study	89
Central nervous system involvement in patients with Richter transformation of chronic lymphocytic leukemia (CLL): the Mayo Clinic experience	89
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management	84
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT	82
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma	80
A multiparametric niche-like drug screening platform in acute myeloid leukemia	69
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M	66
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease	66
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency	62
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma	60
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes	59
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity	59
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma	57
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort	56
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor	55
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma	53
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma	52
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid	51

In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study	51
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients	50
Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL	50
Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma	49
Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute promyelocytic leukemia	49
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression	48
Assessing the performance of the Iceland screens, treats, or prevents multiple myeloma (iStopMM) model in a multicultural Bronx cohort: implications for monoclonal gammopathy of undetermined significa	48
CALRins5-mediated clonal hematopoiesis causes severe hemolytic anemia in a female PGK1Ser320Asn carrier	48
Association of ciltacabtagene autoleucel with immune effector cell-associated enterocolitis: insights from a large national database	47
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome	46
Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment	46
Impact of SARS-CoV-2 vaccination on monoclonal gammopathy of undetermined significance: results from the population-based iStopMM study	46
Genome profiling with targeted adaptive sampling long-read sequencing for pediatric leukemia	44
Molecular variants, clonal evolution and clinical relevance in pediatric and adult T-cell lymphoblastic neoplasia	44
Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia	43
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study	42
Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: insights from real-world genomic data	42
Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies	40
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review	40
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma	40
RSK1 dependency in FLT3-ITD acute myeloid leukemia	40
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression	38
The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy	37
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review	37
Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party	37
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma	37
Triple-negative primary myelofibrosis: a comparative analysis of phenotype, genotype, and outcome	36
Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma	36
Adult AML with NUP98 rearrangements should be stratified into adverse-risk group	36
Characteristics and predictors of central nervous system relapse in newly diagnosed acute promyelocytic leukemia in the era of arsenic: a 13-year monocenter cohort study	35
Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity	35
Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations	35
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis	35
Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models	35
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors	35
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma	34
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma	34
Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma	34
Bispecific antibodies in the treatment of multiple myeloma	33
Management of chronic myeloid leukemia in 2023 – common ground and common sense	33
Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia	33
Extended DaraKRd: Are we enhancing outcomes by prolonging treatment?	32
Deep immune cell profiling in blood and bone marrow of early stage monoclonal gammopathy: an iStopMM and ECRIN-M3 collaborative study	32
Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)	31
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma	31
Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years	30
Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999	30
Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians	30
Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial	30
Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection	30

Prognostic and therapeutic implications of TP53 expression in chronic myelomonocytic leukemia	29
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide	29
Smoldering multiple myeloma current treatment algorithms	28
Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study	28
Clinical characteristics and outcomes of 476 mantle cell lymphoma patients aged 80 years and older	28
Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)	28
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial	28
Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study	28
Risk of lymphoid malignancy associated with cancer predisposition genes	28
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)	27
Correction: TET2 deficiency promotes MDS-associated leukemogenesis	27
Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases	27
Improving outcomes with anti-BCMA bispecific antibodies with attention to infection	27
Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study	27
Outcomes of relapse after teclistamab therapy in multiple myeloma	26
Primary cells from patients with adult T cell leukemia/lymphoma depend on HTLV-1 Tax expression for NF-κB activation and survival	26
Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma	26
Donor cell-derived genetic abnormalities after sex mismatched allogeneic cell transplantation: a unique challenge of donor cell leukemia	26
Coincidence of cutaneous blastic plasmacytoid dendritic cell neoplasm and myelodysplastic syndrome derived from clonal hematopoiesis	26
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma	25
Fertility and parenthood in patients with acute promyelocytic leukemia treated with Arsenic Trioxide and All-Trans retinoic acid	24
Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation	24
Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS	24
Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemia	24
Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients	24
Targeting lysine demethylase 5 (KDM5) in mantle cell lymphoma	24
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial	23
Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4	23
Genomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemia	23
MYC-rearranged mature B-cell lymphomas in children and young adults are molecularly Burkitt Lymphoma	23
Drug development in higher-risk myelodysplastic syndromes	23
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial	23
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk	23
Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms	23
Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study	23
Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms	22
Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients	22
Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy	22
Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy	22
Reducing the risks of nuclear war—the role of health professionals	22
Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma	21
Haploidentical vs matched sibling donor transplant for paroxysmal nocturnal haemoglobinuria: A multicenter study	21
Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression	21
Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia	21
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma	21
CHIP amplifies the risk of lymphoid malignancies in individuals with monoclonal B-cell lymphocytosis (MBL)	21
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation	20
Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities	20
Breakthrough infections in MPN-COVID vaccinated patients	20
Management of hematological toxicities after BCMA-directed CAR-T cell therapy	20
Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms	20
Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century	20
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?	20
Late effects in survivors of infant acute lymphoblastic leukaemia—a study of the Australian and New Zealand Children’s Haematology/Oncology Group	20
Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma	20
Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma	19
Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry	19
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study	19
The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis	19
Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recomm	19
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes	19
Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy	19
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages	19
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib	18
Survival trends in hematological malignancies in the Nordic countries through 50 years	18
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis	18
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in t	18
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab	18
Mendelian randomization of immune cell phenotypes to discover potential drug targets for B-cell malignancy	18
Correction: Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study	18
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience	18
Current treatment algorithm: diffuse large B cell lymphoma	18
Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies	18
Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML	18
Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party	18
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group	17
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases	17
Incidental vs. symptomatic diagnosis of follicular lymphoma: implications of earlier detection	17
Granulocyte colony-stimulating factor plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia: a multicenter phase 2 trial	17
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms	17

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study	17
Prognostic impact of organ involvement in aggressive adult T-cell leukemia/lymphoma: definition of risk organ and proposal of a prognostic index	17
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies	17
The constitutive activation of STAT3 gene and its mutations are at the crossroad between LGL leukemia and autoimmune disorders	17
Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival	17
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia	17
EBV+ polymorphic B-cell lymphoproliferative disorder, NOS: a single-center study of a newly recognized pathologic entity	17
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison	16
Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study	16
Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation	16
IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) for patients with relapsed or refractory acute lymphoblastic leukemia: phase 1 trial	16
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis	16
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm	16
Transposable elements as genome regulators in normal and malignant haematopoiesis	16
Early growth response 1 as a key regulator of PD-L1 expression and immune evasion in extranodal NK/T-cell lymphoma	16
Real-world treatment patterns and clinical outcomes among patients with diffuse large B-cell lymphoma in a US healthcare claims database	16
Real-world decline in survival with poor guideline adherence in chronic myeloid leukemia care	15
DDX41 germline variants causing donor cell leukemia indicate a need for further genetic workup in the context of hematopoietic stem cell transplantation	15
Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance	15
Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study	15
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma	15
Combined MEK and JAK inhibition reduces osteopontin plasma level and bone marrow fibrosis in a myelofibrosis mouse model	15
The expanding CML treatment landscape: an introspective commentary	15
The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma	15
Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study	15
Allogeneic stem cell transplantation from variant-carrying family donors leads to long-term engraftment in Telomere Biology Disorders	15
I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients	15
An atlas of the bone marrow bone proteome in patients with dysproteinemias	14
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy	14
Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine–venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net	14
Patient preferences for intervention in the setting of precursor multiple myeloma	14
Conditional survival in multiple myeloma and impact of prognostic factors over time	14
Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing data	14
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee	14
Mode of progression in smoldering multiple myeloma: a study of 406 patients	14
Resistance to targeted therapies: delving into FLT3 and IDH	14
Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study	13
Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry	13
Utilization of real-world evidence in regulatory approvals for multiple myeloma therapies	13
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel	13
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma	13
Myeloid neoplasm occurrence during stable molecular remission of NPM1-mutated AML: are we facing secondary disease or AML relapse?	13
Frequent and clinically relevant germline DNA repair gene variants in young and familial myeloproliferative neoplasms	13
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome	13
Diabetes mellitus in multiple myeloma and related plasma cell disorders: a review of risk, prognosis, and outcomes	13
Utility of flow cytometry screening before MRD testing in multiple myeloma	13
Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL	13
Assessing drivers of disparate outcomes and applicability of risk stratification in a cohort of patients with myelofibrosis	13
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission	13
Site-specific prognosis and temporal trends in extranodal marginal zone lymphoma patients in the United States	13
Eltrombopag with or without Tacrolimus for relapsed/refractory acquired aplastic anaemia: a prospective randomized trial	13